Assignee
MYELOID THERAPEUTICS INC
US·12 granted patents·28 pending applications·51 citations·filing 2020–2025
Top patents by PatentIndex Score
40 records- 0196US11918605B1Chimeric antigen receptor dendritic cell (CAR-DC) for treatment of cancerMYELOID THERAPEUTICS INC·Filed 2022·Granted Mar 5, 2024·6 cites·30 claims
- 0296US11517589B2Chimeric antigen receptor dendritic cell (CAR-DC) for treatment of cancerMYELOID THERAPEUTICS INC·Filed 2022·Granted Dec 6, 2022·9 cites·23 claims
- 0396US11026973B2Engineered phagocytic receptor compositions and methods of use thereofMYELOID THERAPEUTICS INC·Filed 2020·Granted Jun 8, 2021·6 cites·16 claims
- 0496US11013764B2Engineered phagocytic receptor compositions and methods of use thereofMYELOID THERAPEUTICS INC·Filed 2020·Granted May 25, 2021·6 cites·14 claims
- 0596US10980836B1Therapeutic cell compositions and methods of manufacturing and use thereofMYELOID THERAPEUTICS INC·Filed 2020·Granted Apr 20, 2021·15 cites·21 claims
- 0695US11918604B2Chimeric antigen receptor dendritic cell (CAR-DC) for treatment of cancerMYELOID THERAPEUTICS INC·Filed 2022·Granted Mar 5, 2024·3 cites·25 claims
- 0794US11628218B2Engineered chimeric fusion protein compositions and methods of use thereofMYELOID THERAPEUTICS INC·Filed 2022·Granted Apr 18, 2023·3 cites·22 claims
- 0891US11672874B2Methods and compositions for genomic integrationMYELOID THERAPEUTICS INC·Filed 2021·Granted Jun 13, 2023·2 cites·26 claims
- 0988US12319925B2Methods and compositions for genomic integrationMYELOID THERAPEUTICS INC·Filed 2023·Granted Jun 3, 2025·1 cites·21 claims
- 1087US2024207309A1Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancerMYELOID THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1180US2022175831A1Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancerMYELOID THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1280US2022175830A1Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancerMYELOID THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1380US2022202856A1Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancerMYELOID THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1479US11944680B2Engineered chimeric fusion protein compositions and methods of use thereofMYELOID THERAPEUTICS INC·Filed 2023·Granted Apr 2, 2024·0 cites·20 claims
- 1579US2023364265A1Methods and compositions for genomic integrationMYELOID THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1679US2022118010A1Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancerMYELOID THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1778US2024252630A1Engineered chimeric fusion protein compositions and methods of use thereofMYELOID THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1876US2021252053A1Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancerMYELOID THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1975US2022411817A1Methods and compositions for genomic integrationMYELOID THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2075US2022364110A1Methods and compositions for genomic integrationMYELOID THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2175US2024391998A1Engineered chimeric fusion protein compositions and methods of use thereofMYELOID THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2274US2022184230A1Methods and compositions for genomic integrationMYELOID THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2372US12030938B2Engineered chimeric fusion protein compositions and methods of use thereofMYELOID THERAPEUTICS INC·Filed 2023·Granted Jul 9, 2024·0 cites·30 claims
- 2468US2025090663A1Binding domains and methods of use thereofMYELOID THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2567US2021299172A1Engineered phagocytic receptor compositions and methods of use thereofMYELOID THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2667US2024327482A1Macrophage specific engager compositions and methods of use thereofMYELOID THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2767US2024148785A1Therapeutic cell compositions and methods for manufacture and uses thereofMYELOID THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2866US2024182543A1Engineered chimeric fusion protein compositions and methods of use thereofMYELOID THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2965US2024139241A1Compositions and methods for conditioning patients for cell therapyMYELOID THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3065US2024139314A1Engineered chimeric fusion protein compositions and methods of use thereofMYELOID THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3165US2025250584A1Methods and compositions for genomic integrationMYELOID THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 3264US12252545B2Therapeutic cell compositions and methods of manufacturing and use thereofMYELOID THERAPEUTICS INC·Filed 2021·Granted Mar 18, 2025·0 cites·17 claims
- 3362US2023263888A1Monocytes inducing antigen-specific tolerance, engineered monocytes, and method of use thereofMYELOID THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3460US2023374538A1Methods and Compositions for Expression of Nucleic Acids in CellsMYELOID THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3557US2023046472A1Therapeutic cell compositions and methods of manufacturing and use thereofMYELOID THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3656US2022001031A1Engineered chimeric fusion protein compositions and methods of use thereofMYELOID THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3752US2025276064A1Engineered chimeric fusion protein compositions and methods of use thereofMYELOID THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 3851US2022241428A1Macrophage specific engager compositions and methods of use thereofMYELOID THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 3951US2022378824A1Engineered chimeric fusion protein compositions and methods of use thereofMYELOID THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 4050US2025249099A1Compositions for cell-specific expression and uses thereofMYELOID THERAPEUTICS INC·Filed 2025·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →